US Biotech’s “Top Insider” Keynotes At ANZA

US Biotech’s “Top Insider” Keynotes At ANZA Tech Net Showcase

First ever event gives biotech companies access to US market opportunities, expansion and industry contacts
SAN Francisco, Calif., April 6, 2002 – ANZA Technology Network (ANZA Tech Net), the premier networking organization promoting US and Australian/New Zealand technology business collaboration, today announced Dr Cynthia Robbins-Roth as a keynote speaker at the first ever ANZA Technology Showcase to be held in the US (San Francisco, June 2-4, 2002).

Named by Forbes magazine as one of the biotech industry’s “top insiders”, Dr Roth will share with delegates the business of biotech in the US – covering the key issues of funding, partnerships, IP and the history and future of the industry.

Dr Roth, former Genentech research scientist, is the founder of BioVenture Consultants which provides strategic planning and technical business assessment to the biotech and VC industry Her biotech columns appear regularly in national US publications such as Forbes.

Dr Roth said she was looking forward to seeing some of the best biotech out of Australia and New Zealand and is pleased to be involved in the exchange of information between the US and these innovative countries.

“Australia and New Zealand are set to really take advantage of this relatively young and fast moving sector – you have great research facilities and a highly educated population and a strong background in innovation and discovery in the sector,” she said.

“The challenge will be to move into overseas markets and the ANZA Tech Net Showcase provides the ideal forum for companies looking to expansion, partnerships and collaboration.”

She said Biotech’s Golden Age lies ahead.

“As we begin the 21st Century literally hundreds of new biotech projects begun in the last decade are poised to power into the market place,” Dr Roth said.

“This explosion will fuel opportunities for investors and employees alike and we will all benefit from the products.”

“Every day the industry labs generate more information about how our bodies work, in sickness and in health, down to the single molecule level.

“For the first time in history, it is possible to design treatments for diseases such as Alzheimer’s disease, Lou Gehrigs’s disease, breast and prostate cancer and heart disease – and aim those drugs directly at molecular causes of the disease. More effective drugs with fewer nasty side effects will be possible because of biotechnology,” she said.

ANZA Tech Net Chairman Guy Manson said the organization was particularly honored to have Dr Roth as keynote.
“Not only will Dr Roth be able to provide a close-up on the US biotech industry, she is also an invaluable facilitator for executives wanting to develop contacts in the industry,” he said.

He said there would also be an opportunity for delegates to receive a signed copy of Dr Roth’s biotech industry best seller “The business of Biotech – from Alchemy to IPO” – the number one recommendation on the Bay Area Bio Science Center site.

Leading New Zealand companies are expected to participate in the Showcase, presenting their business propositions to executives from some of North America’s largest and most innovative tech, biotech and business services organizations.

The Showcase will also feature business forums – addressing key issues that affect companies looking to establish a presence or conduct business development in the US.

ENDS

© Scoop Media